Opus Genetics, INC Form 4 insider transactions

Benjamin R Yerxa, President and a Director of Opus Genetics, Inc., sold 7,429 shares of common stock on July 23, 2026 for $2.97 per share.

Joseph K Schachle, Chief Operating Officer of Opus Genetics, Inc., sold 4,644 shares of common stock on July 23, 2026 for $2.94 per share.

George Magrath, Chief Executive Officer and a Director of Opus Genetics, Inc., sold 9,475 shares of common stock on July 23, 2026 for $2.95 per share.

Robert E. Gagnon, Chief Financial Officer of Opus Genetics, Inc., sold 7,783 shares of common stock on July 23, 2026 for $2.95 per share.

Foundation Fighting Blindness Retinal Degeneration Fund sold 1.7 million shares of Opus Genetics, Inc. at $4.35 per share.

Benjamin R. Yerxa, President of Opus Genetics, sold 7,470 shares to satisfy tax withholding obligations related to RSU vesting.

Chief Operating Officer Joseph K. Schachle sold 4,697 shares of Opus Genetics to cover tax obligations related to RSU vesting.

CEO George Magrath sold 9,511 shares of Opus Genetics to satisfy tax obligations related to restricted stock unit vesting.

Chief Scientific & Development Officer Ashwath Jayagopal sold 7,542 shares of Opus Genetics to cover tax obligations.

CFO Robert E. Gagnon sold 7,842 shares of Opus Genetics to cover tax obligations related to restricted stock unit vesting.

Director Richard J. Rodgers was granted 24,367 restricted stock units in Opus Genetics, Inc. on April 20, 2026.

Director James S.J. Manuso was granted 24,367 restricted stock units in Opus Genetics, Inc. as part of a compensation event.

Director Adrienne L. Graves was granted 24,367 restricted stock units in Opus Genetics, Inc. as part of a standard equity compensation arrangement.

Director Cam Gallagher was granted 24,367 restricted stock units in Opus Genetics, Inc. as part of a standard equity compensation arrangement.

Opus Genetics director Susan Benton was granted 24,367 restricted stock units as part of an equity compensation plan.

Director Jean Bennett was granted 24,367 restricted stock units in Opus Genetics, Inc. as part of a compensation arrangement.

Director Sean Ainsworth was granted 24,367 restricted stock units in Opus Genetics, Inc. as part of a compensation event.

Opus Genetics' Chief Operating Officer, Joseph K. Schachle, sold 3,719 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Opus Genetics' Head of Financial Quality Assurance, Amy Zaremba Rabourn, sold 2,816 shares of common stock to cover tax withholding obligations from a restricted stock unit award.

Opus Genetics CEO George Magrath sold 24,438 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Opus Genetics' Chief Scientific & Development Officer, Ashwath Jayagopal, sold 3,719 shares of common stock to cover tax withholding obligations.

Opus Genetics, Inc. granted 400,000 restricted stock units to President and Director Benjamin R. Yerxa, vesting over four years.

Opus Genetics' Chief Operating Officer, Joseph K. Schachle, was granted 250,000 restricted stock units, vesting over four years.

Opus Genetics' Head of Financial Quality Assurance, Amy Zaremba, was granted 86,500 restricted stock units.

Opus Genetics, Inc. CEO and Director George Magrath acquired 483,639 shares of common stock through a restricted stock unit grant.

Opus Genetics, Inc. reported a grant of 400,000 restricted stock units to its Chief Scientific & Development Officer, Ashwath Jayagopal, vesting over four years.

Opus Genetics' Chief Financial Officer, Robert E. Gagnon, was granted 400,000 restricted stock units, vesting quarterly over four years.

Opus Genetics' Head of Financial Quality Assurance, Amy Zaremba, reported a disposition of 3,390 common shares to cover tax obligations related to an RSU vesting.

Amy Zaremba Rabourn, Head of Financial Quality Assurance at Opus Genetics, reported the disposition of 3,950 common shares for tax withholding purposes.

Opus Genetics Director Cam Gallagher was granted 67,000 restricted stock units, vesting in December 2026.